search
Back to results

Efficacy and Safety of TD-1473 in Crohn's Disease (DIONE)

Primary Purpose

Crohn's Disease

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Placebo
TD-1473
Sponsored by
Theravance Biopharma
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Crohn's Disease focused on measuring TD-1473, Janus kinase inhibitor, JAK inhibitor, Inflammatory Bowel Disease, IBD, Crohn's Disease, Intestinal restriction

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Is at least 18 years of age at screening
  • Males and females with clinical evidence of Crohn's disease for at least 3 months duration at screening
  • Moderately-to-severely active Crohn's Disease at baseline, as defined by a Crohn's Disease Activity Index (CDAI) score of 220-450 inclusive
  • SES-CD score of ≥ 3 with ulceration (corresponding to a score of 1) in at least 1 of the 5 ileocolonic segments on the Ulcerated Surface subscore of the SES-CD]
  • Is corticosteroid-dependent or has demonstrated inadequate response, or intolerance to conventional therapy (aminosalicylates, corticosteroids and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate) or biologics (e.g., anti-TNF therapy, anti-IL-12/23 (anti-interleukin), anti-integrin).
  • Additional inclusion criteria apply

Exclusion Criteria:

  • Is currently receiving biologic (anti-TNF, anti-integrin, or anti-IL12/23) therapy
  • Has a current bacterial, parasitic, fungal, or viral infection
  • Has clinically significant abnormalities in laboratory evaluations
  • Prior exposure or potential exposure to a JAK inhibitor that was stopped due to intolerance or lack of efficacy
  • Subject has participated in another clinical trial of an investigational drug (or medical device) within 30 days prior to Screening or 5x the half-life of the investigational drug, whichever is longer, or is currently participating in another trial of an investigational drug (or medical device)
  • Subject has failed ≥ 3 biologic agents of 3 different mechanisms of action (i.e., anti-TNF, anti-integrin, and anti-IL12/23)
  • Additional exclusion criteria apply

Sites / Locations

  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • PMG Research of Salisbury
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Active Treatment TD-1473 with Dose A

Active Treatment TD-1473 with Dose B

Placebo

Arm Description

1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks.

1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 48 additional weeks.

1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks.

Outcomes

Primary Outcome Measures

Change From Baseline in Crohn's Disease Activity Index (CDAI) Score
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Benchmarks for disease activity as measured by the CDAI were: <150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and >450, very severe disease.

Secondary Outcome Measures

Number of Participants Who Demonstrated a Clinical Response as Measured by CDAI
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Benchmarks for disease activity as measured by the CDAI were: <150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and >450, very severe disease. Clinical response was defined as a reduction from baseline of ≥100 points or CDAI <150
Number of Participants Who Demonstrated CDAI Clinical Remission
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Benchmarks for disease activity as measured by the CDAI were: <150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and >450, very severe disease. CDAI clinical remission was defined as a CDAI score less than 150 at Week 12.
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12
The SES-CD incorporated 4 descriptors: the ulcer size, the proportion of surface covered by ulcer, the proportion of surface covered by other lesions, and the presence of stenosis. Each descriptor was scored in 5 segments (ileum, right colon, transverse colon, left colon, and rectum). The total score ranged from 0 to 56, with higher scores indicating a worse outcome.
Number of Participants With Endoscopic Response at Week 12
Endoscopic Response was defined as a reduction of SES-CD score or Endoscopic Remission (defined as SES-CD ≤ 2) at Week 12.
Number of Participants With Stool Frequency and Abdominal Pain (SFAP) Clinical Remission
SFAP clinical remission was defined as an abdominal pain score ≤1 (on a scale of 0-3 with 0 representing 'no pain' and 3 representing 'severe pain'), stool frequency ≤2.8, and both not worse than baseline at Week 12.

Full Information

First Posted
July 31, 2018
Last Updated
February 14, 2023
Sponsor
Theravance Biopharma
search

1. Study Identification

Unique Protocol Identification Number
NCT03635112
Brief Title
Efficacy and Safety of TD-1473 in Crohn's Disease
Acronym
DIONE
Official Title
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Terminated
Why Stopped
The study was terminated by the sponsor on 16 November 2021 after a planned review by the Independent Data Monitoring Committee.
Study Start Date
November 19, 2018 (Actual)
Primary Completion Date
December 30, 2021 (Actual)
Study Completion Date
December 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theravance Biopharma

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.
Detailed Description
A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 12 weeks of induction therapy with TD˗1473 in subjects with moderately-to-severely active Crohn's Disease. This study includes 3 phases: Screening, Induction, and Active Treatment Extension (ATE). The Induction phase of the study is a randomized, double blind, placebo controlled, parallel group study evaluating 2 oral dose levels of TD-1473 compared to placebo for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will continue to receive TD-1473 in the ATE, for up to 48 additional weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn's Disease
Keywords
TD-1473, Janus kinase inhibitor, JAK inhibitor, Inflammatory Bowel Disease, IBD, Crohn's Disease, Intestinal restriction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
167 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active Treatment TD-1473 with Dose A
Arm Type
Active Comparator
Arm Description
1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks.
Arm Title
Active Treatment TD-1473 with Dose B
Arm Type
Active Comparator
Arm Description
1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 48 additional weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
Intervention Type
Drug
Intervention Name(s)
TD-1473
Intervention Description
TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
Primary Outcome Measure Information:
Title
Change From Baseline in Crohn's Disease Activity Index (CDAI) Score
Description
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Benchmarks for disease activity as measured by the CDAI were: <150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and >450, very severe disease.
Time Frame
Baseline to Week 12
Secondary Outcome Measure Information:
Title
Number of Participants Who Demonstrated a Clinical Response as Measured by CDAI
Description
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Benchmarks for disease activity as measured by the CDAI were: <150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and >450, very severe disease. Clinical response was defined as a reduction from baseline of ≥100 points or CDAI <150
Time Frame
Week 12
Title
Number of Participants Who Demonstrated CDAI Clinical Remission
Description
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Benchmarks for disease activity as measured by the CDAI were: <150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and >450, very severe disease. CDAI clinical remission was defined as a CDAI score less than 150 at Week 12.
Time Frame
Week 12
Title
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12
Description
The SES-CD incorporated 4 descriptors: the ulcer size, the proportion of surface covered by ulcer, the proportion of surface covered by other lesions, and the presence of stenosis. Each descriptor was scored in 5 segments (ileum, right colon, transverse colon, left colon, and rectum). The total score ranged from 0 to 56, with higher scores indicating a worse outcome.
Time Frame
Baseline to Week 12
Title
Number of Participants With Endoscopic Response at Week 12
Description
Endoscopic Response was defined as a reduction of SES-CD score or Endoscopic Remission (defined as SES-CD ≤ 2) at Week 12.
Time Frame
Week 12
Title
Number of Participants With Stool Frequency and Abdominal Pain (SFAP) Clinical Remission
Description
SFAP clinical remission was defined as an abdominal pain score ≤1 (on a scale of 0-3 with 0 representing 'no pain' and 3 representing 'severe pain'), stool frequency ≤2.8, and both not worse than baseline at Week 12.
Time Frame
Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is at least 18 years of age at screening Males and females with clinical evidence of Crohn's disease for at least 3 months duration at screening Moderately-to-severely active Crohn's Disease at baseline, as defined by a Crohn's Disease Activity Index (CDAI) score of 220-450 inclusive SES-CD score of ≥ 3 with ulceration (corresponding to a score of 1) in at least 1 of the 5 ileocolonic segments on the Ulcerated Surface subscore of the SES-CD] Is corticosteroid-dependent or has demonstrated inadequate response, or intolerance to conventional therapy (aminosalicylates, corticosteroids and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate) or biologics (e.g., anti-TNF therapy, anti-IL-12/23 (anti-interleukin), anti-integrin). Additional inclusion criteria apply Exclusion Criteria: Is currently receiving biologic (anti-TNF, anti-integrin, or anti-IL12/23) therapy Has a current bacterial, parasitic, fungal, or viral infection Has clinically significant abnormalities in laboratory evaluations Prior exposure or potential exposure to a JAK inhibitor that was stopped due to intolerance or lack of efficacy Subject has participated in another clinical trial of an investigational drug (or medical device) within 30 days prior to Screening or 5x the half-life of the investigational drug, whichever is longer, or is currently participating in another trial of an investigational drug (or medical device) Subject has failed ≥ 3 biologic agents of 3 different mechanisms of action (i.e., anti-TNF, anti-integrin, and anti-IL12/23) Additional exclusion criteria apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Theravance Biopharma
Official's Role
Study Director
Facility Information:
Facility Name
Theravance Biopharma Investigational Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233-2110
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36688
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85259-5499
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Oakland
State/Province
California
ZIP/Postal Code
94612
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Aventura
State/Province
Florida
ZIP/Postal Code
33180
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33765
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33013
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Largo
State/Province
Florida
ZIP/Postal Code
33777
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33135
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
New Port Richey
State/Province
Florida
ZIP/Postal Code
34653
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33710
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33603
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
New Lenox
State/Province
Illinois
ZIP/Postal Code
60451
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20850
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Brockton
State/Province
Massachusetts
ZIP/Postal Code
02302
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Wyoming
State/Province
Michigan
ZIP/Postal Code
49519
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89133
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Utica
State/Province
New York
ZIP/Postal Code
13502
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Gastonia
State/Province
North Carolina
ZIP/Postal Code
28504
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
Facility Name
PMG Research of Salisbury
City
Salisbury
State/Province
North Carolina
ZIP/Postal Code
28144
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74136
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15212
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Uniontown
State/Province
Pennsylvania
ZIP/Postal Code
15401
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Orangeburg
State/Province
South Carolina
ZIP/Postal Code
29118
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Rock Hill
State/Province
South Carolina
ZIP/Postal Code
29732
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Boerne
State/Province
Texas
ZIP/Postal Code
78006
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
El Paso
State/Province
Texas
ZIP/Postal Code
79936
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Garland
State/Province
Texas
ZIP/Postal Code
75044
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Harlingen
State/Province
Texas
ZIP/Postal Code
78550
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77058
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78215
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Southlake
State/Province
Texas
ZIP/Postal Code
76092
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Spring
State/Province
Texas
ZIP/Postal Code
77386
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Lansdowne Town Center
State/Province
Virginia
ZIP/Postal Code
20176
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Bankstown
State/Province
New South Wales
ZIP/Postal Code
2200
Country
Australia
Facility Name
Theravance Biopharma Investigational Site
City
Elizabeth Vale
State/Province
South Australia
ZIP/Postal Code
5112
Country
Australia
Facility Name
Theravance Biopharma Investigational Site
City
Perth
State/Province
Western Australia
ZIP/Postal Code
6000
Country
Australia
Facility Name
Theravance Biopharma Investigational Site
City
Klagenfurt am Wörthersee
State/Province
Carinthia
ZIP/Postal Code
9020
Country
Austria
Facility Name
Theravance Biopharma Investigational Site
City
Innsbruck
State/Province
Tyrol
ZIP/Postal Code
6020
Country
Austria
Facility Name
Theravance Biopharma Investigational Site
City
Wien
State/Province
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Theravance Biopharma Investigational Site
City
Sofia
State/Province
Sofiya
ZIP/Postal Code
1303
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Sofia
State/Province
Sofiya
ZIP/Postal Code
1336
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Sofia
State/Province
Sofiya
ZIP/Postal Code
1431
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Sofia
State/Province
Sofiya
ZIP/Postal Code
1527
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Sofia
State/Province
Sofiya
ZIP/Postal Code
1784
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Targovishte
State/Province
Turgovishte
ZIP/Postal Code
7700
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Dobrich
ZIP/Postal Code
9300
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Plovdiv
ZIP/Postal Code
4004
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Sliven
ZIP/Postal Code
8800
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Stara Zagora
ZIP/Postal Code
6000
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Stara Zagora
ZIP/Postal Code
6001
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Veliko Tarnovo
ZIP/Postal Code
5000
Country
Bulgaria
Facility Name
Theravance Biopharma Investigational Site
City
Osijek
State/Province
Osijek-baranja
ZIP/Postal Code
31 000
Country
Croatia
Facility Name
Theravance Biopharma Investigational Site
City
Rijeka
ZIP/Postal Code
51000
Country
Croatia
Facility Name
Theravance Biopharma Investigational Site
City
Split
ZIP/Postal Code
21000
Country
Croatia
Facility Name
Theravance Biopharma Investigational Site
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Facility Name
Theravance Biopharma Investigational Site
City
Saint Etienne
State/Province
Auvergne
ZIP/Postal Code
42055
Country
France
Facility Name
Theravance Biopharma Investigational Site
City
Reims
State/Province
Champagne-ardenne
ZIP/Postal Code
51092
Country
France
Facility Name
Theravance Biopharma Investigational Site
City
Colombes
State/Province
Ile-de-france
ZIP/Postal Code
92701
Country
France
Facility Name
Theravance Biopharma Investigational Site
City
Toulouse
State/Province
Midi-pyrenees
ZIP/Postal Code
31059
Country
France
Facility Name
Theravance Biopharma Investigational Site
City
Nice
State/Province
Provence Alpes COTE D'azur
ZIP/Postal Code
06202
Country
France
Facility Name
Theravance Biopharma Investigational Site
City
Pierre-Bénite
State/Province
Rhone-alpes
ZIP/Postal Code
69495
Country
France
Facility Name
Theravance Biopharma Investigational Site
City
Clichy
ZIP/Postal Code
92110
Country
France
Facility Name
Theravance Biopharma Investigational Site
City
Vandœuvre-lès-Nancy
ZIP/Postal Code
54511
Country
France
Facility Name
Theravance Biopharma Investigational Site
City
Tbilisi
ZIP/Postal Code
0114
Country
Georgia
Facility Name
Theravance Biopharma Investigational Site
City
Tbilisi
ZIP/Postal Code
0159
Country
Georgia
Facility Name
Theravance Biopharma Investigational Site
City
München
State/Province
Bayern
ZIP/Postal Code
80331
Country
Germany
Facility Name
Theravance Biopharma Investigational Site
City
München
State/Province
Bayern
ZIP/Postal Code
81377
Country
Germany
Facility Name
Theravance Biopharma Investigational Site
City
Hannover
State/Province
Niedersachsen
ZIP/Postal Code
30625
Country
Germany
Facility Name
Theravance Biopharma Investigational Site
City
Kiel
State/Province
Schleswig-holstein
ZIP/Postal Code
24105
Country
Germany
Facility Name
Theravance Biopharma Investigational Site
City
Berlin
ZIP/Postal Code
14050
Country
Germany
Facility Name
Theravance Biopharma Investigational Site
City
Hamburg
ZIP/Postal Code
22559
Country
Germany
Facility Name
Theravance Biopharma Investigational Site
City
Athens
State/Province
Attica
ZIP/Postal Code
115 27
Country
Greece
Facility Name
Theravance Biopharma Investigational Site
City
Heraklion
State/Province
Crete
ZIP/Postal Code
71110
Country
Greece
Facility Name
Theravance Biopharma Investigational Site
City
Baja
State/Province
Bacs-kiskun
ZIP/Postal Code
6500
Country
Hungary
Facility Name
Theravance Biopharma Investigational Site
City
Debrecen
State/Province
Hajdu-bihar
ZIP/Postal Code
4032
Country
Hungary
Facility Name
Theravance Biopharma Investigational Site
City
Gyöngyös
State/Province
Heves
ZIP/Postal Code
3200
Country
Hungary
Facility Name
Theravance Biopharma Investigational Site
City
Budapest
ZIP/Postal Code
H-1088
Country
Hungary
Facility Name
Theravance Biopharma Investigational Site
City
Be'er Ya'aqov
State/Province
Rehoboth
ZIP/Postal Code
7030000
Country
Israel
Facility Name
Theravance Biopharma Investigational Site
City
Rehovot
State/Province
Rehoboth
ZIP/Postal Code
7661041
Country
Israel
Facility Name
Theravance Biopharma Investigational Site
City
Kfar Saba
State/Province
Sharon
ZIP/Postal Code
4428164
Country
Israel
Facility Name
Theravance Biopharma Investigational Site
City
Haifa
ZIP/Postal Code
3339419
Country
Israel
Facility Name
Theravance Biopharma Investigational Site
City
Holon
ZIP/Postal Code
5822012
Country
Israel
Facility Name
Theravance Biopharma Investigational Site
City
Jerusalem
ZIP/Postal Code
9362410
Country
Israel
Facility Name
Theravance Biopharma Investigational Site
City
Nahariya
ZIP/Postal Code
2210001
Country
Israel
Facility Name
Theravance Biopharma Investigational Site
City
Petah Tikva
ZIP/Postal Code
4941492
Country
Israel
Facility Name
Theravance Biopharma Investigational Site
City
Tel Aviv
ZIP/Postal Code
6423906
Country
Israel
Facility Name
Theravance Biopharma Investigational Site
City
Wŏnju
State/Province
Gangwon-Do
ZIP/Postal Code
26426
Country
Korea, Republic of
Facility Name
Theravance Biopharma Investigational Site
City
Guri-si
State/Province
Gyeonggi-do
ZIP/Postal Code
11923
Country
Korea, Republic of
Facility Name
Theravance Biopharma Investigational Site
City
Seongnam-si
State/Province
Gyeonggi-Do
ZIP/Postal Code
13496
Country
Korea, Republic of
Facility Name
Theravance Biopharma Investigational Site
City
Busan
ZIP/Postal Code
48108
Country
Korea, Republic of
Facility Name
Theravance Biopharma Investigational Site
City
Daegu
ZIP/Postal Code
42601
Country
Korea, Republic of
Facility Name
Theravance Biopharma Investigational Site
City
Seoul
ZIP/Postal Code
02447
Country
Korea, Republic of
Facility Name
Theravance Biopharma Investigational Site
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Facility Name
Theravance Biopharma Investigational Site
City
Hamilton
State/Province
Waikato
ZIP/Postal Code
3204
Country
New Zealand
Facility Name
Theravance Biopharma Investigational Site
City
Lower Hutt
State/Province
Wellington
ZIP/Postal Code
5010
Country
New Zealand
Facility Name
Theravance Biopharma Investigational Site
City
Wroclaw
State/Province
Dolnoslaskie
ZIP/Postal Code
52416
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Wrocław
State/Province
Dolnoslaskie
ZIP/Postal Code
53-333
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Włocławek
State/Province
Kujawsko-Pomorskie
ZIP/Postal Code
87-800
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Lodz
State/Province
Lodzkie
ZIP/Postal Code
90302
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Lodz
State/Province
Lodzkie
ZIP/Postal Code
91363
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Łódź
State/Province
Lodzkie
ZIP/Postal Code
91-034
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Kraków
State/Province
Malopolskie
ZIP/Postal Code
31501
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Warszawa
State/Province
Masovian
ZIP/Postal Code
00-728
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
00635
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-653
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-781
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
03-580
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Rzeszow
State/Province
Podkarpackie
ZIP/Postal Code
35302
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Sopot
State/Province
Pomorskie
ZIP/Postal Code
81-756
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Tychy
State/Province
Slaskie
ZIP/Postal Code
43 100
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Poznań
State/Province
Wielkopolskie
ZIP/Postal Code
61-113
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Szczecin
State/Province
Zachodnio-Pomorskie
ZIP/Postal Code
71434
Country
Poland
Facility Name
Theravance Biopharma Investigational Site
City
Braga
ZIP/Postal Code
4700-308
Country
Portugal
Facility Name
Theravance Biopharma Investigational Site
City
Guimarães
ZIP/Postal Code
4835-044
Country
Portugal
Facility Name
Theravance Biopharma Investigational Site
City
Leiria
ZIP/Postal Code
2410-197
Country
Portugal
Facility Name
Theravance Biopharma Investigational Site
City
Lisboa
ZIP/Postal Code
1500-458
Country
Portugal
Facility Name
Theravance Biopharma Investigational Site
City
Santa Maria da Feira
ZIP/Postal Code
4520-211
Country
Portugal
Facility Name
Theravance Biopharma Investigational Site
City
Setúbal
ZIP/Postal Code
2910-446
Country
Portugal
Facility Name
Theravance Biopharma Investigational Site
City
Vila Nova De Gaia
ZIP/Postal Code
4434-502
Country
Portugal
Facility Name
Theravance Biopharma Investigational Site
City
Oradea
State/Province
Bihor
ZIP/Postal Code
410066
Country
Romania
Facility Name
Theravance Biopharma Investigational Site
City
Bucharest
State/Province
Bucuresti
ZIP/Postal Code
020125
Country
Romania
Facility Name
Theravance Biopharma Investigational Site
City
Cluj-Napoca
State/Province
Cluj
ZIP/Postal Code
400162
Country
Romania
Facility Name
Theravance Biopharma Investigational Site
City
Timisoara
State/Province
Timis
ZIP/Postal Code
300167
Country
Romania
Facility Name
Theravance Biopharma Investigational Site
City
Timişoara
State/Province
Timis
ZIP/Postal Code
300002
Country
Romania
Facility Name
Theravance Biopharma Investigational Site
City
Bucuresti
ZIP/Postal Code
050098
Country
Romania
Facility Name
Theravance Biopharma Investigational Site
City
Cluj
ZIP/Postal Code
400006
Country
Romania
Facility Name
Theravance Biopharma Investigational Site
City
Moscow
State/Province
Moscow City
ZIP/Postal Code
127015
Country
Russian Federation
Facility Name
Theravance Biopharma Investigational Site
City
Rostov-on-Don
State/Province
Rostov
ZIP/Postal Code
344022
Country
Russian Federation
Facility Name
Theravance Biopharma Investigational Site
City
Samara
State/Province
Samarskaya Oblast
ZIP/Postal Code
443041
Country
Russian Federation
Facility Name
Theravance Biopharma Investigational Site
City
Novosibirsk
ZIP/Postal Code
630005
Country
Russian Federation
Facility Name
Theravance Biopharma Investigational Site
City
Novosibirsk
ZIP/Postal Code
630087
Country
Russian Federation
Facility Name
Theravance Biopharma Investigational Site
City
Saint Petersburg
ZIP/Postal Code
196247
Country
Russian Federation
Facility Name
Theravance Biopharma Investigational Site
City
Saint-Petersburg
ZIP/Postal Code
195257
Country
Russian Federation
Facility Name
Theravance Biopharma Investigational Site
City
Saratov
ZIP/Postal Code
410053
Country
Russian Federation
Facility Name
Theravance Biopharma Investigational Site
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Theravance Biopharma Investigational Site
City
Belgrade
ZIP/Postal Code
11080
Country
Serbia
Facility Name
Theravance Biopharma Investigational Site
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
Facility Name
Theravance Biopharma Investigational Site
City
Niš
ZIP/Postal Code
18000
Country
Serbia
Facility Name
Theravance Biopharma Investigational Site
City
Subotica
ZIP/Postal Code
24000
Country
Serbia
Facility Name
Theravance Biopharma Investigational Site
City
Zrenjanin
ZIP/Postal Code
23000
Country
Serbia
Facility Name
Theravance Biopharma Investigational Site
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
1619
Country
South Africa
Facility Name
Theravance Biopharma Investigational Site
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2196
Country
South Africa
Facility Name
Theravance Biopharma Investigational Site
City
Lenasia
State/Province
Gauteng
ZIP/Postal Code
1827
Country
South Africa
Facility Name
Theravance Biopharma Investigational Site
City
Claremont
State/Province
Western Cape
ZIP/Postal Code
7708
Country
South Africa
Facility Name
Theravance Biopharma Investigational Site
City
Las Palmas De Gran Canaria
State/Province
Las Palmas
ZIP/Postal Code
35010
Country
Spain
Facility Name
Theravance Biopharma Investigational Site
City
Barcelona
ZIP/Postal Code
08022
Country
Spain
Facility Name
Theravance Biopharma Investigational Site
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Theravance Biopharma Investigational Site
City
Huelva
ZIP/Postal Code
21005
Country
Spain
Facility Name
Theravance Biopharma Investigational Site
City
Madrid
ZIP/Postal Code
28922
Country
Spain
Facility Name
Theravance Biopharma Investigational Site
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Facility Name
Theravance Biopharma Investigational Site
City
Kiev
State/Province
Kiev City
ZIP/Postal Code
04107
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Kyiv
State/Province
Kiev City
ZIP/Postal Code
01030
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Kyiv
State/Province
Kiev
ZIP/Postal Code
01133
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Kremenchuk
State/Province
Poltava
ZIP/Postal Code
39617
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Úzhgorod
State/Province
Transcarpathian
ZIP/Postal Code
88000
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Úzhgorod
State/Province
Transcarpathia
ZIP/Postal Code
88009
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Chernivtsi
ZIP/Postal Code
58001
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Kharkiv
ZIP/Postal Code
61037
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Kharkiv
ZIP/Postal Code
61039
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Kharkiv
ZIP/Postal Code
61137
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Lviv
ZIP/Postal Code
79059
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Vinnytsia
ZIP/Postal Code
21005
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Zaporizhzhya
ZIP/Postal Code
69104
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Zaporizhzhya
ZIP/Postal Code
69600
Country
Ukraine
Facility Name
Theravance Biopharma Investigational Site
City
Blackpool
State/Province
England
ZIP/Postal Code
FY3 8NR
Country
United Kingdom
Facility Name
Theravance Biopharma Investigational Site
City
London
State/Province
England
ZIP/Postal Code
NW1 2PG
Country
United Kingdom
Facility Name
Theravance Biopharma Investigational Site
City
Glasgow
State/Province
Scotland
ZIP/Postal Code
G51 4TF
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.

Learn more about this trial

Efficacy and Safety of TD-1473 in Crohn's Disease

We'll reach out to this number within 24 hrs